Regencell Bioscience Holdings Ltd
RGCNasdaq
$5.02
↑ +5.0%Jul 17 close · end-of-day
Price
1Y↓ -67.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.5B
Enterprise Value
$2.5B
P/E
—
P/S
—
P/B
510.7
EV/EBITDA
—
PEG
—
FCF Yield
-0.1%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$3.6M
Free Cash Flow (TTM)
-$3.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-73.8%
ROIC
-125.0%
Debt / Equity
—
Net Cash
$2.5M
Return 1Y
-66.2%
Company profile
Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
- CEO
- Yat-Gai Au
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Website
- regencellbioscience.com
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$1.4M | -$7.6M | -$6.3M | -$4.7M | -$3.8M |
| Net income | -$1.3M | -$7.4M | -$5.9M | -$4.3M | -$3.6M |
| Diluted EPS | -$0.13 | -$0.58 | -$1.19 | -$0.87 | -$0.72 |
| Operating cash flow | -$767,311.00 | -$5.3M | -$5.0M | -$4.0M | -$3.1M |
| Free cash flow | — | -$6.0M | -$5.0M | -$4.0M | -$3.3M |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
No quarterly data.
Company news
Apr 27, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.